[Ventricular fibrillation in chronic heart disease]

Area of Science:

• Cardiology
• Electrophysiology
• Internal Medicine

Context:

• Spontaneous ventricular fibrillation (VF) poses a significant risk of sudden cardiac death.
• Effective antiarrhythmic treatment strategies are crucial for patients post-VF, especially after acute cardiac events are ruled out.
• Understanding treatment efficacy based on patient subgroups (e.g., revascularization status) is vital for clinical decision-making.

Purpose:

• To describe antiarrhythmic treatment strategies in patients with spontaneous ventricular fibrillation after acute cardiac disease elimination.
• To prospectively evaluate the effectiveness of these antiarrhythmic treatments.
• To assess the impact of revascularization and programmed ventricular stimulation on treatment outcomes.

Summary:

• 36 patients with spontaneous VF were analyzed, divided into subgroups based on myocardial revascularization status.
• Programmed ventricular stimulation was used to test antiarrhythmic drugs (primarily amiodarone), and implantable cardioverter-defibrillators (ICDs) were implanted in 17 patients.
• Outcomes included cardiac deaths and sudden arrhythmic deaths, with ICD implantation showing benefit across all subgroups, irrespective of revascularization.

Impact:

• The study confirms the life-saving benefit of ICD implantation for patients experiencing spontaneous VF.
• It highlights the limitations of antiarrhythmic drug testing in predicting outcomes compared to ICD efficacy.
• Findings support universal ICD consideration for VF survivors, independent of underlying cardiac conditions or revascularization procedures.